LivaNova PLC [LIVN] stock is trading at $55.24, down -1.07%. An important factor to consider is whether the stock is rising or falling in short-term value. The LIVN shares have gain 2.41% over the last week, with a monthly amount glided 5.02%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 21, March 2024, LivaNova to Announce First-Quarter 2024 Results. In a post published today on Yahoo Finance, LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2024 results prior to the call.
From an analyst’s perspective:
LivaNova PLC [NASDAQ: LIVN] stock has seen the most recent analyst activity on March 20, 2024, when Needham reiterated its Buy rating. Previously, Mizuho upgraded its rating to Buy on February 20, 2024, and elevated its price target to $70. On September 06, 2023, HSBC Securities initiated with a Hold rating and assigned a price target of $52 on the stock. Robert W. Baird started tracking the stock assigning a Neutral rating and suggested a price target of $56 on July 19, 2023. Mizuho initiated its recommendation with a Neutral and recommended $48 as its price target on April 14, 2023. Barclays started tracking with a Equal Weight rating for this stock on December 21, 2022, and assigned it a price target of $62. In a note dated April 06, 2022, Wolfe Research initiated an Outperform rating and provided a target price of $95 on this stock.
LivaNova PLC [LIVN] stock has fluctuated between $42.25 and $59.86 over the past year. Currently, Wall Street analysts expect the stock to reach $69.5 within the next 12 months. LivaNova PLC [NASDAQ: LIVN] shares were valued at $55.24 at the most recent close of the market. An investor can expect a potential return of 25.81% based on the average LIVN price forecast.
Analyzing the LIVN fundamentals
LivaNova PLC [NASDAQ:LIVN] reported sales of 1.15B for the trailing twelve months, which represents a growth of 12.80%. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at -0.06%, Pretax Profit Margin comes in at -0.07%, and Net Profit Margin reading is 0.02%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.01 and Total Capital is -0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 54.50 points at the first support level, and at 53.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 55.82, and for the 2nd resistance point, it is at 56.41.
LivaNova PLC [LIVN] reported earnings per share of $0.87 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.77/share, meaning a difference of $0.1 and a surprise factor of 13.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.73 per share as compared to estimates of $0.64 per share, a difference of $0.09 representing a surprise of 14.10%.
Ratios To Look Out For
For context, LivaNova PLC’s Current Ratio is 2.95. On the other hand, the Quick Ratio is 2.51, and the Cash Ratio is 1.73. Considering the valuation of this stock, the price to sales ratio is 2.58, the price to book ratio is 2.33 and price to earnings (TTM) ratio is 171.34.
